Ignite Creation Date:
2025-12-24 @ 4:09 PM
Ignite Modification Date:
2026-03-21 @ 8:54 PM
Study NCT ID:
NCT04079166
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-19
First Post:
2019-08-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Sponsor:
Scancell Ltd
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
SCIB1-002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None